| US 7,329,639 B2 | ||
| Peptide useful in immunomodulation | ||
| Britta Hardy, Tel Aviv (Israel); Annat Raiter, Kfar Saba (Israel); and Leah Klapper, Givataim (Israel) | ||
| Assigned to CureTech Ltd., Yavne (Israel); and Mor-Research Applications Ltd., Petach Tikya (Israel) | ||
| Filed on Apr. 27, 2006, as Appl. No. 11/411,832. | ||
| Application 11/411832 is a continuation of application No. 10/821283, filed on Apr. 09, 2004, granted, now 7,122,372. | ||
| Application 10/821283 is a continuation of application No. PCT/IL02/00831, filed on Oct. 15, 2002. | ||
| Claims priority of application No. 145926 (IL), filed on Oct. 15, 2001. | ||
| Prior Publication US 2006/0210573 A1, Sep. 21, 2006 | ||
| Int. Cl. C07K 14/00 (2006.01) | ||
| U.S. Cl. 514—2 [530/350] | 11 Claims |
| 1. An isolated peptide comprising at least one epitope that is recognized by and binds to a BAT monoclonal antibody, said
peptide selected from the group consisting of:
(a) a peptide having the sequence of any one of SEQ ID NOs: 1, 2 and 6 through 10;
(b) a peptide having at least 90% identity with a peptide of (a); and
(c) a combination of peptides according to (a) or (b).
|